GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
22 Outubro 2024 - 10:00AM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical technology company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
today announced that it will participate in the 2024 BioFuture
Conference, to be held at Cure in New York City from October 28-30,
2024.
Paul V. Goode, President & Chief Executive
Officer of Glucotrack, will present on Tuesday, October 29, 2024,
at 11:00 AM ET and will hold one-on-one meetings. The presentation
will provide an update on the development of the Company’s
continuous blood glucose monitor (“CBGM”) for people with diabetes.
Qualified investors and media are invited to
apply for complimentary registration.
This year’s BioFuture program explores topics
including next-generation applications of quantum computing and
biology, alternative financing, how artificial intelligence (“AI”)
will impact healthcare, the use of psychedelics in mental health
treatments, bioethical challenges, and more. Speakers from
Regeneron Pharmaceuticals, Ipsen, IBM, Rock Health, Ray
Therapeutics, Mineralys Therapeutics, Andreessen Horowitz (a16z),
and JP Morgan, among many others, will bring insights into the
major trends shaping the future of healthcare.
For more information about Glucotrack’s CBGM,
visit glucotrack.com. Information on the Company’s website does not
constitute a part of and is not incorporated by reference into this
press release.
# # #
About BioFuture
BioFuture is where relentless therapeutic
pioneers, innovators, and investors gather to assess and shape the
future of healthcare and digital health. Participate in candid,
unfiltered discussions. At this year’s summit, attendees will
explore the exciting convergence between rapidly evolving fields
including biopharma, digital medicine, big data, AI, healthcare
systems, payors, and more. The coming decade will dramatically
accelerate the transformation of the healthcare ecosystem. For more
information, please visit www.biofuture.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2023 as filed with the SEC on March
28, 2024.
Contacts:
Investor Relations:investors@glucotrack.com
Lisa WilsonIn-Site CommunicationsT: 917-543-9932E:
lwilson@insitecony.com
Media:GlucotrackPR@icrinc.com
GlucoTrack (NASDAQ:GCTK)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
GlucoTrack (NASDAQ:GCTK)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024